Literature DB >> 28255439

Case report of a switch to mania induced by lurasidone.

Mark Kanzawa1, Olga Hadden2.   

Abstract

Entities:  

Year:  2016        PMID： 28255439      PMCID： PMC5315232          DOI： 10.1177/2045125316677954

Source DB:  PubMed          Journal:  Ther Adv Psychopharmacol        ISSN： 2045-1253


× No keyword cloud information.
  10 in total

Review 1.  Dopamine D2 receptor occupancy and clinical effects: a systematic review and pooled analysis.

Authors:  Hiroyuki Uchida; Hiroyoshi Takeuchi; Ariel Graff-Guerrero; Takefumi Suzuki; Koichiro Watanabe; David C Mamo
Journal:  J Clin Psychopharmacol       Date:  2011-08       Impact factor: 3.153

Review 2.  Low-dose quetiapine induced or worsened mania in the context of possible undertreatment.

Authors:  Hun Y Millard; Barbara A Wilson; Douglas L Noordsy
Journal:  J Am Board Fam Med       Date:  2015 Jan-Feb       Impact factor: 2.657

Review 3.  Antipsychotic polypharmacy in psychotic disorders: a critical review of neurobiology, efficacy, tolerability and cost effectiveness.

Authors:  Marc W H Lochmann van Bennekom; Harm J Gijsman; Frans G Zitman
Journal:  J Psychopharmacol       Date:  2013-02-14       Impact factor: 4.153

Review 4.  Atypical antipsychotic-induced mania/hypomania: a review of recent case reports and clinical studies.

Authors:  Amine Benyamina; Ludovic Samalin
Journal:  Int J Psychiatry Clin Pract       Date:  2011-08-31       Impact factor: 1.812

5.  5-HT1A and 5-HT7 receptors contribute to lurasidone-induced dopamine efflux.

Authors:  Mei Huang; Masakuni Horiguchi; Anna R Felix; Herbert Y Meltzer
Journal:  Neuroreport       Date:  2012-05-09       Impact factor: 1.837

6.  Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity.

Authors:  Tadashi Ishibashi; Tomoko Horisawa; Kumiko Tokuda; Takeo Ishiyama; Masaaki Ogasa; Rie Tagashira; Kenji Matsumoto; Hiroyuki Nishikawa; Yoko Ueda; Satoko Toma; Hitomi Oki; Norihiko Tanno; Ikutaro Saji; Akira Ito; Yukihiro Ohno; Mitsutaka Nakamura
Journal:  J Pharmacol Exp Ther       Date:  2010-04-19       Impact factor: 4.030

Review 7.  Manic/hypomanic symptoms induced by atypical antipsychotics: a review of the reported cases.

Authors:  Panayiota G Michalopoulou; Lefteris Lykouras
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2006-01-25       Impact factor: 5.067

8.  A network meta-analysis on comparative efficacy and all-cause discontinuation of antimanic treatments in acute bipolar mania.

Authors:  A Yildiz; M Nikodem; E Vieta; C U Correll; R J Baldessarini
Journal:  Psychol Med       Date:  2014-07-18       Impact factor: 7.723

Review 9.  Lurasidone for the treatment of bipolar depression: an evidence-based review.

Authors:  Rachel Franklin; Sam Zorowitz; Andrew K Corse; Alik S Widge; Thilo Deckersbach
Journal:  Neuropsychiatr Dis Treat       Date:  2015-08-19       Impact factor: 2.570

10.  Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology.

Authors:  G M Goodwin; P M Haddad; I N Ferrier; J K Aronson; Trh Barnes; A Cipriani; D R Coghill; S Fazel; J R Geddes; H Grunze; E A Holmes; O Howes; S Hudson; N Hunt; I Jones; I C Macmillan; H McAllister-Williams; D R Miklowitz; R Morriss; M Munafò; C Paton; B J Saharkian; Kea Saunders; Jma Sinclair; D Taylor; E Vieta; A H Young
Journal:  J Psychopharmacol       Date:  2016-03-15       Impact factor: 4.153
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.